Lytgobi® (futibatinib) – New orphan drug approval
September 30, 2022 - Taiho Oncology’s announced the FDA approval of Lytgobi (futibatinib), for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
Top